Merrimack Pharmaceuticals Inc.
101 Binney Street
285 articles with Merrimack Pharmaceuticals Inc.
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2020 financial results for the period ended December 31, 2020.
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2020 financial results for the period ended September 30, 2020. “We are pleased that both Ipsen Pharmaceuticals and Elevation Oncology continue to enroll patients in separate clinical stage programs which could result in milestone payments to Merrimack,” said Gary Crocker, Chairman of Merrimack’s Board of
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its second quarter 2020 financial results for the period ended June 30, 2020. “We are pleased by recent news releases from both Ipsen Pharmaceuticals and Elevation Oncology, which are conducting separate programs which could result in milestone payments to Merrimack. Ipsen announced receipt of Fast Track designation from th
Merrimack Pharmaceuticals, Inc. announced its first quarter 2020 financial results for the period ended March 31, 2020.
Merrimack Pharmaceuticals, Inc. announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical nanoliposome programs to Celator Pharmaceuticals, Inc.
As a result of this milestone payment, Merrimack’s Board of Directors has authorized and declared a special cash dividend of $6.7 million on the Company’s common stock
The Plan is designed to protect the Company’s ability to use its valuable net operating loss carryforwards and certain other valuable tax attributes.
JFL Capital Management, LLC (together with its affiliates, "JFL Capital"), the largest stockholder of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK), with ownership of approximately 9.4% of the Company's outstanding shares, announced today that it has withdrawn its solicitation in connection with the Company's 2019 annual meeting of stockholders (the "Annual Meeting").
9/20/2019Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments.
Company Enters into Cooperation Agreement with Newtyn Management and Western Standard
Merrimack Pharmaceuticals Announces Per Share Amount for Previously Declared Special Dividend - September 5, 2019
Merrimack Pharmaceuticals announced that the dividend amount for the previously authorized and declared $20 million special cash dividend (the “Special Dividend”) announced on July 25, 2019 is $1.496675 per outstanding share of Merrimack common stock.
Company’s Board has Taken Crucial Actions to Maximize Shareholder Value and Preserve More than $500 Million in Potential Future Milestone Payments
Believes Significant Destruction of Value and Lack of Alignment with Stockholders Warrants an Overhaul in the Boardroom
Merrimack Pharmaceuticals (Nasdaq: MACK) (the “Company” or “Merrimack”) announced today it is rescheduling its 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”) for October 17, 2019.
The special dividend is payable on September 5, 2019 to stockholders of record as of the close of business on August 28, 2019.
7/2/2019A month after beleaguered Merrimack Pharmaceuticals announced it was terminating its staff and leadership team, the company’s chief executive officer and chief financial officer have resigned their positions. But, they are both remaining with the company as high-paid consultants.
Hundreds lose their jobs as companies close facilities and shift business focuses.
Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related milestones resulting from its 2017 asset sale to Ipsen S.A
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced its first quarter 2019 financial results for the period ended March 31, 2019.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc..